DERIVATIVES OF 2-[[N-(AMINOCARBONYL)-N-HYDROXYAMINO]METHYL]-1,4-BENZODIOXAN AS ORALLY-ACTIVE 5-LIPOXYGENASE INHIBITORS

被引:36
作者
SATOH, Y
POWERS, C
TOLEDO, LM
KOWALSKI, TJ
PETERS, PA
KIMBLE, EF
机构
[1] Research Department, Pharmaceuticals Division, CIBA-GEIGY Corporation, Summit, New Jersey 07901
关键词
D O I
10.1021/jm00001a012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-Hydroxyureas based on the 1,4-benzodioxan template were prepared from appropriately substituted 1,4-benzodioxan-2-methanols as the key intermediates and evaluated in the in vitro guinea pig polymorphonuclear leukocyte 5-lipoxygenase (5-LO) assay for their 5-LO inhibitory activity. Placement of a 7-phenoxy or 7-p-fluorophenoxy substituent resulted in a dramatic increase in in vitro potency. Selected compounds were subsequently assayed in an ex vivo dog model of LTB(4) synthesis at a dose of 1.0 mg/kg. The 7-phenoxy derivatives 16 and 17 showed modest duration of action (DA) in this dog model. The g-regioisomers 21 and 22 were less potent. Replacement of the 7-phenoxy group of 16 with the p-fluorophenoxy moiety enhanced the DA dramatically. Compound 18 (CGS 25667), which had an IC50 value of 100 nM in the in vitro guinea pig 5-LO assay, had a DA of 8.5 h (zileuton, DA = 8.5 h) at the oral dose of 1.0 mg/kg. Optical antipodes (24, 26) of 18 were independently synthesized in high (>95%) enantiomeric purity from commercially available optically active glycidyl tosylates and evaluated. In the in vitro assay, the 2S-(-)-enantiomer (24, CGS 25997, IC50 = 85 nM) was found to be twice as active as the 2R-(+)-counterpart (26, CGS 25998, IC50 - 180 nM). In the ex vivo experiment, 24, which dose dependently inhibited plasma 5-LO activity, was shown to be significantly longer acting than 26, with a DA of 8.4 h when dosed orally at 1.0 mg/kg.
引用
收藏
页码:68 / 75
页数:8
相关论文
共 46 条
  • [1] S-[1-(2,3-DIAMINOPHENOXY)]-3'-(N-TERT-BUTYLAMINO)PROPAN-2'-OL - SIMPLIFIED ASYMMETRIC-SYNTHESIS WITH CD AND CHIRAL HPLC ANALYSIS
    AIGBIRHIO, F
    PIKE, VW
    FRANCOTTE, E
    WATERS, SL
    BANFIELD, B
    JAEGGI, KA
    DRAKE, A
    [J]. TETRAHEDRON-ASYMMETRY, 1992, 3 (04) : 539 - 554
  • [2] Batt D G, 1992, Prog Med Chem, V29, P1, DOI 10.1016/S0079-6468(08)70004-3
  • [3] THE DISCOVERY AND DEVELOPMENT OF ZILEUTON - AN ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR
    BELL, RL
    YOUNG, PR
    ALBERT, D
    LANNI, C
    SUMMERS, JB
    BROOKS, DW
    RUBIN, P
    CARTER, GW
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (03): : 505 - 510
  • [4] THE ROLE OF LEUKOTRIENE ANTAGONISTS AND INHIBITORS IN THE TREATMENT OF AIRWAY DISEASE
    BUSSE, WW
    GADDY, JN
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (05): : S103 - S107
  • [5] CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929
  • [6] CLARK RD, 1985, HETEROCYCLES, V23, P2005
  • [7] COLLAWN C, 1992, AM J GASTROENTEROL, V87, P342
  • [8] RATIONALLY DESIGNED, POTENT COMPETITIVE INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
    COREY, EJ
    CASHMAN, JR
    KANTNER, SS
    WRIGHT, SW
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (05) : 1503 - 1504
  • [9] METHOXYTETRAHYDROPYRANS - A NEW SERIES OF SELECTIVE AND ORALLY POTENT 5-LIPOXYGENASE INHIBITORS
    CRAWLEY, GC
    DOWELL, RI
    EDWARDS, PN
    FOSTER, SJ
    MCMILLAN, RM
    WALKER, ERH
    WATERSON, D
    BIRD, TGC
    BRUNEAU, P
    GIRODEAU, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (14) : 2600 - 2609
  • [10] SHORT AND ENANTIOSELECTIVE SYNTHESES OF (R)-2-HYDROXYMETHYL-1,4-BENZODIOXAN AND (S)-2-HYDROXYMETHYL-1,4-BENZODIOXAN
    DELGADO, A
    LECLERC, G
    LOBATO, C
    MAULEON, D
    [J]. TETRAHEDRON LETTERS, 1988, 29 (30) : 3671 - 3674